People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2015 |
| Bonum Therapeutics, Inc. | — | Biotechnology | Series C | $46.2M | $746.1M | 2022 |
| Good Therapeutics, Inc. | — | Biotechnology | Series B | $31.1M | $188.6M | 2018 |
| EpiBiologics, Inc. | — | Biotechnology | Series B | $30.0M | $569.5M | 2022 |
| Pandion Therapeutics, Inc. | — | Biotechnology | Series B | $21.6M | $857.3M | 2018 |
Mitchell Mutz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mitchell Mutz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| NICHOLAS WALROD | 2 | 8 |
| John McKearn | 2 | 6 |
| Karl Handelsman | 2 | 3 |
| Diane Hollenbaugh | 2 | 3 |
| John Mulligan | 2 | 3 |
| Monique Schiersing | 2 | 2 |
| Neela Patel | 2 | 2 |
| Samuel Bjork | 2 | 2 |
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| Alan Crane | 1 | 9 |
| Alexandra Cantley | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| Carlo Rizzuto | 1 | 7 |
| Alan Fuhrman | 1 | 5 |
| Paul Grint | 1 | 5 |
| Vikas Goyal | 1 | 5 |
| James Wells | 1 | 4 |
| Johan Kordel | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.